Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-Current Deffered Revenue (2016 - 2025)

Editas Medicine (EDIT) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $54.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $54.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $54.2 million, a 0.0% change, with the full-year FY2024 number at $54.2 million, down 10.65% from a year prior.
  • Non-Current Deffered Revenue was $54.2 million for Q3 2025 at Editas Medicine, roughly flat from $54.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $68.9 million in Q2 2022 to a low of $54.2 million in Q1 2024.
  • A 5-year average of $58.5 million and a median of $60.7 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 60.1% in 2021, then rose 24.75% in 2022.
  • Editas Medicine's Non-Current Deffered Revenue stood at $60.9 million in 2021, then dropped by 0.36% to $60.7 million in 2022, then changed by 0.0% to $60.7 million in 2023, then fell by 10.65% to $54.2 million in 2024, then changed by 0.0% to $54.2 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Non-Current Deffered Revenue are $54.2 million (Q3 2025), $54.2 million (Q2 2025), and $54.2 million (Q1 2025).